NIH Discovers Why GLP-1 Weight Loss Drugs Plateau and How to Fix It
New NIH research reveals the brain-cell signaling mechanism behind GLP-1 drug plateaus and a potential way to extend their effects.
20 articles
New NIH research reveals the brain-cell signaling mechanism behind GLP-1 drug plateaus and a potential way to extend their effects.
New research identifies FTL1 protein as key driver of brain aging. Reducing it restored memory and neural connections in mice.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
MIT's self-organizing laser creates ultra-sharp brain images 25x faster, enabling real-time tracking of drugs crossing the blood-brain barrier.
Declining Menin in the hypothalamus drives inflammation and aging. Restoring it reversed decline; D-serine amino acid improved cognition in mice.
New research reveals that brain cells active after workouts—not just during—are key to building endurance over time.
New research reveals GLP-1 drugs like Ozempic significantly reduce depression, anxiety, and substance use disorders alongside weight management.
Researchers created modified psilocin that maintains antidepressant effects while dramatically reducing psychedelic side effects in mice.
Duke researchers restored healthy mitochondria to damaged nerve cells, cutting pain-related behaviors by 50% in mice with nerve pain.
Clinical trial shows solriamfetol significantly improves alertness and performance in workers who start before sunrise.
Speed-of-processing training in adults 65+ showed lasting protection against dementia in groundbreaking 20-year study.
UC San Diego study shows one week of intensive meditation produces measurable brain changes and enhanced neuroplasticity comparable to psychedelic effects.
Raising Sox9 levels in aging astrocytes reduced amyloid plaque buildup and protected memory in mouse models with existing Alzheimer's symptoms.
Researchers finally discovered lecanemab activates brain immune cells through a specific antibody fragment to clear toxic plaques.
A 12-week clinical trial found older adults taking probiotics with antidepressants had greater reductions in depression and anxiety than placebo.
A study of 100,000 people found semaglutide users had 44% lower depression risk and 42% fewer psychiatric hospitalizations.
Researchers finally discovered how lecanemab clears brain plaques by activating immune cells through a specific antibody fragment.
A new tool that boosts mitochondrial activity in neurons restored memory in dementia mice, suggesting energy failure drives Alzheimer's symptoms.
Scientists discover harmful bacterial sugars in the gut trigger immune attacks that damage the brain in ALS and dementia patients.
Cambridge researchers found a gene network that shuts off nerve repair — and an existing hormone drug that reactivates it.